medigraphic.com

2022, Número 3

Siguiente >>

Rev Hematol Mex 2022; 23 (3)


Análisis de la incidencia del linfoma difuso de células B grandes y el linfoma folicular en tres países de América Central y el Caribe (República Dominicana, Guatemala y Panamá)

Álvarez-Alvarado AM, López-Barquero A, Buitrón N, Quiel D, Cumba T, Matos C, Vasallo R, Torselli S

Idioma: Español
Referencias bibliográficas: 34
Paginas: 131-141
Archivo PDF: 253.95 Kb.


RESUMEN

Objetivo: Determinar la incidencia y la recaída o resistencia de dos tipos de linfoma no Hodgkin (linfoma difuso de células B grandes y linfoma folicular) en República Dominicana, Guatemala y Panamá entre 2014 y 2018.
Materiales y Métodos: Estudio retrospectivo, observacional, multicéntrico, de cohortes, efectuado en pacientes mayores de 18 años con diagnóstico de linfoma no Hodgkin. Se recolectaron retrospectivamente datos demográficos y clínicos.
Resultados: Se incluyeron 443 pacientes con linfoma no Hodgkin. La edad media al diagnóstico fue de 56.2 ± 16.9 años, el 54% eran varones. La tasa bruta de incidencia global del linfoma no Hodgkin por país y tipo fue de 5.9 por cada 100,000 personas en Panamá, 1.4/100,000 personas en República Dominicana y 0.4/100,000 personas en Guatemala. La estimación de la tasa bruta de incidencia del linfoma no Hodgkin por países se mantuvo estable en el periodo analizado.
Conclusiones: La población con linfoma no Hodgkin de Centroamérica y el Caribe muestra características similares a las mundiales. La elección del tratamiento de linfoma difuso de células B grandes y linfoma folicular corresponde a las recomendaciones de las principales guías clínicas internacionales. La incidencia del linfoma no Hodgkin es menor en Centroamérica y el Caribe que en otras regiones del mundo, pero la edad al momento del diagnóstico es 10 años menor.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet 2017; 390 (10091): 298-310.doi: 10.1016/S0140-6736(16)32407-2.

  2. Swerdlow SH, Campo E, Harris NL, et al. WHO classificationof tumours of haematopoietic and lymphoid tissues:International agency for research on cancer. Lyon; 2008.

  3. Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R.Global patterns and trends in the incidence of non-Hodgkinlymphoma. Cancer Causes Control 2019; 30 (5): 489-99.doi: 10.1007/s10552-019-01155-5. Epub 2019 Mar 20.

  4. Thandra KC, Barsouk A, Saginala K, Anand-Padala S. Epidemiologyof non-Hodgkin's lymphoma. Med Sci (Basel)2021; 9 (1): 5. doi: 10.3390/medsci9010005.

  5. Howlader N, Noone AM, Krapcho M, et al. SEER CancerStatistics Review, 1975-2016. https://seer.cancer.gov/csr/1975_2016/: National Cancer Institute. Bethesda, MD.

  6. GLOBOCAN. Estimated number of new cases in 2020,non-Hodgkin lymphoma, both sexes, all ages https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=34&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=12022

  7. Cerhan JR, Slager SL. Familial predisposition and geneticrisk factors for lymphoma. Blood 2015; 126 (20): 2265-73.doi: 10.1182/blood-2015-04-537498.

  8. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneityamong non-Hodgkin lymphoma subtypes: theInterLymph Non-Hodgkin Lymphoma Subtypes Project.J Natl Cancer Inst Monogr 2014; 2014 (48): 130-44. doi:10.1093/jncimonographs/lgu013.

  9. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl JMed 2021; 384 (9): 842-58. doi: 10.1056/NEJMra2027612.

  10. Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse largeB cell lymphoma: A review of current data and potentialapplications on risk stratification and management. AmJ Hematol 2021; 96 (5): 617-29. doi: 10.1002/ajh.26151.

  11. Carbone A, Roulland S, Gloghini A, Younes A, et al. Follicularlymphoma. Nat Rev Dis Primers 2019; 5 (1): 83. doi:10.1038/s41572-019-0132-x.

  12. Dreyling M, Ghielmini M, Rule S, Salles G, et al. Newlydiagnosed and relapsed follicular lymphoma: ESMOClinical Practice Guidelines for diagnosis, treatment andfollow-up. Ann Oncol 2021; 32 (3): 298-308. doi: 10.1016/j.annonc.2020.11.008.

  13. Prica A, Hay AE, Crump M, et al. Evaluating the indirectcosts of care associated with salvage chemotherapy forrelapsed and refractory aggressive-histology lymphoma: Asubset analysis of the Canadian Cancer Trials Group (CCTG)LY.12 Clinical Trial. Curr Oncol 2021; 28 (2): 1256-61. doi:10.3390/curroncol28020119.

  14. Breslow NE, Day NE. Statistical Methods in Cancer Research:The Design and Analysis of Cohort Studies. 1stUS-1st Printing edition. Lyon: Oxford University Press,Incorporated; 1988: 418.

  15. Cancer.org. Factores de riesgo para el linfoma no Hodgkinhttps://www.cancer.org/es/cancer/linfoma-no-hodgkin/causas-riesgos-prevencion/factores-de-riesgo.html2022.

  16. Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis andtreatment. Am Fam Physician 2020; 101 (1): 34-41.

  17. Cabrera ME, Martinez V, Nathwani BN, Muller-HermelinkH, et al. Non-Hodgkin lymphoma in Chile: a review of 207consecutive adult cases by a panel of five expert hematopathologists.Leuk Lymphoma 2012; 53 (7): 1311-7. doi:10.3109/10428194.2012.654471.

  18. Dotlic S, Perry AM, Petrusevska G, Fetica B, et al. Classificationof non-Hodgkin lymphoma in South-eastern Europe:review of 632 cases from the international non-Hodgkinlymphoma classification project. Br J Haematol 2015; 171(3): 366-72. doi: 10.1111/bjh.13586.

  19. Laurini JA, Perry AM, Boilesen E, Diebold J, et al. Classificationof non-Hodgkin lymphoma in Central and SouthAmerica: a review of 1028 cases. Blood 2012; 120 (24):4795-801. doi: 10.1182/blood-2012-07-440073.

  20. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidencepatterns by WHO subtype in the United States,1992-2001. Blood 2006; 107 (1): 265-76. doi: 10.1182/blood-2005-06-2508.

  21. Perry AM, Diebold J, Nathwani BN, MacLennan K, et al.Non-Hodgkin lymphoma in the Far East: review of 730cases from the international non-Hodgkin lymphomaclassification project. Ann Hematol 2016; 95 (2): 245-51.doi: 10.1007/s00277-015-2543-4.

  22. Perry AM, Perner Y, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in Southern Africa: review of 487cases from The International Non-Hodgkin LymphomaClassification Project. Br J Haematol 2016; 172 (5): 716-23.doi: 10.1111/bjh.13885.

  23. Kim H, Shin AR, Chung HH, Kim MK, et al. Recent trends inhepatitis B virus infection in the general Korean population.Korean J Intern Med 2013; 28 (4): 413-9. doi: 10.3904/kjim.2013.28.4.413.

  24. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC,Murphy EL. Global epidemiology of HTLV-I infection andassociated diseases. Oncogene 2005; 24 (39): 6058-68.doi: 10.1038/sj.onc.1208968.

  25. Cancer.net. Linfoma no Hodgkin: Subtipos de LNH https://www.cancer.net/es/tipos-de-c%C3%A1ncer/linfomano-hodgkin/subtipos-de-lnh#:~:text=El%20linfoma%20mediast%C3%ADnico%20primario%20de,con%20LNH%20tienen%20este%20subtipo.2021.

  26. Freedman A, Jacobsen E. Follicular lymphoma: 2020 updateon diagnosis and management. Am J Hematol 2020; 95 (3):316-27. doi: 10.1002/ajh.25696.

  27. Kanas G, Ge W, Quek RGW, Keeven K, et al. Epidemiologyof diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma(FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma2022; 63 (1): 54-63. doi: 10.1080/10428194.2021.1975188.

  28. Purdum A, Tieu R, Reddy SR, Broder MS. Direct costsassociated with relapsed diffuse large B-cell lymphomatherapies. Oncologist 2019; 24 (9): 1229-36. doi: 10.1634/theoncologist.2018-0490.

  29. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 updateon diagnosis, risk stratification, and treatment. AmJ Hematol 2019; 94 (5): 604-16. doi: 10.1002/ajh.25460.

  30. Luminari S, Cesaretti M, Rashid I, Mammi C, et al. Incidence,clinical characteristics and survival of malignant lymphomas:a population-based study from a cancer registry innorthern Italy. Hematol Oncol 2007; 25 (4): 189-97. https://doi.org/10.1002/hon.826.

  31. United Nations Development Programme. Human developmentprogramme index (HDI). Available from: http://hdr.undp.org/en/content/human-development-index-hdi.2017.

  32. GLOBOCAN. Estimated age-standardized incidencerates (World) in 2020, non-Hodgkin lymphoma, bothsexes, all ages, North America https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=34&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=0&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=3&show_ranking=0&rotate=%255B10%252C0%255D2022

  33. Sant M, Allemani C, Tereanu C, De Angelis R, et al. Incidenceof hematologic malignancies in Europe by morphologicsubtype: results of the HAEMACARE project. Blood 2010;116 (19): 3724-34. doi: 10.1182/blood-2010-05-282632.

  34. GLOBOCAN. Estimated age-standardized incidencerates (World) in 2020, non-Hodgkin lymphoma, bothsexes, all ages https://gco.iarc.fr/today/online-analysismulti-bars?v=2020&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=34&type=0&statistic=5&prevalence=0&population_group=2&ages_group%5B%5D=0&ages_g ro u p % 5 B % 5 D = 1 7 & n b _ i te m s = 1 0 & g ro u p _cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D&population_group_list=32,44,52,84,68,76,152,170,188,192,214,218,222,312,474,254,320,328,332,340,388,484,558,591,600,604,630,662,740,780,858,862&population_group_globocan_id=9042022




2020     |     www.medigraphic.com